Hillstream BioPharma, Inc. (HILS)

NASDAQ: HILS · IEX Real-Time Price · USD
0.600
+0.061 (11.23%)
At close: Jan 27, 2023, 4:00 PM
0.629
+0.029 (4.90%)
After-hours: Jan 27, 2023, 7:16 PM EST

Company Description

Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers.

The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar IC50 against PI3K-delta and HDAC6, which is also known to downregulate; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells.

The company was incorporated in 2017 and is based in Bridgewater, New Jersey.

Hillstream BioPharma, Inc.
Hillstream BioPharma logo
Country United States
Founded 2017
IPO Date Jan 12, 2022
Industry Biotechnology
Sector Healthcare
Employees 1
CEO Mr. Randy D. Milby MBA

Contact Details

Address:
1200 Route 22 East
Bridgewater, New Jersey 08807
United States
Phone 302-743-2995
Website hillstreambio.com

Stock Details

Ticker Symbol HILS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $4.00
CIK Code 0001861657
CUSIP Number 432705101
ISIN Number US4327051011
Employer ID 84-2642541
SIC Code 2834

Key Executives

Name Position
Randy D. Milby MBA President, Chairman and Chief Executive Officer
Thomas P. Hess CPA, MBA Chief Financial Officer

Latest SEC Filings

Date Type Title
Nov 14, 2022 10-Q Quarterly Report
Oct 28, 2022 8-K Current Report
Aug 11, 2022 10-Q Quarterly Report
Aug 9, 2022 8-K Current Report
Jun 23, 2022 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Jun 17, 2022 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Jun 17, 2022 DEF 14A Other definitive proxy statements
May 16, 2022 10-Q Quarterly Report
Apr 1, 2022 10-K Annual Report
Apr 1, 2022 NT 10-K Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405